Plant Name: Boehmeria nivea
Taxonomic Information:
Plant ID: NPO29449
Plant Latin Name: Boehmeria nivea
Taxonomy Genus: Boehmeria
Taxonomy Family: Urticaceae
Plant External Links:
NCBI TaxonomyDB:
83906
Plant-of-the-World-Online:
n.a.
Used in Medicines:
Country/Region:
IndiaTraditional Medicine System:
Indian FolkGeographical Distribution:
India
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ADORA3; ADORA1; ADORA2A; | |
| NPSR1; | |
| ALPL; PIK3CA; PIK3CB; ADK; AKR1B10; ALOX12; GFER; HSD17B10; NQO2; NOX4; POLB; | |
| ACHE; | |
| MET; AXL; FLT3; CDK1; PIM1; KDR; IGF1R; AURKB; | |
| CA2; CA12; CA9; CA14; CA7; CA1; | |
| ESR1; | |
| PTGS2; PTGS1; | |
| NFKB1; | |
| SLCO1B3; | |
| LMNA; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | NQO2 | Quinone reductase 2 | P16083 | CHEMBL3959 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
| Enzyme_unclassified | PIK3CA | PI3-kinase p110-alpha subunit | P42336 | CHEMBL4005 |
| Enzyme_unclassified | PIK3CB | PI3-kinase p110-beta subunit | P42338 | CHEMBL3145 |
| Enzyme_unclassified | ADK | Adenosine kinase | P55263 | CHEMBL3589 |
| Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
| Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
| Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
| Small molecule receptor (family A GPCR) | ADORA1 | Adenosine A1 receptor | P30542 | CHEMBL226 |
| Small molecule receptor (family A GPCR) | ADORA2A | Adenosine A2a receptor | P29274 | CHEMBL251 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.892E-13 | 4.121E-09 | CA1, CA12, CA14, CA2, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 2.561E-10 | 7.968E-07 | CA1, CA12, CA14, CA2, CA7, CA9 |
| BP | GO:0050896; response to stimulus | GO:0006954; inflammatory response | 4.639E-10 | 1.122E-06 | ADORA1, ADORA2A, ADORA3, AXL, NFKB1, NOX4, PIK3CA, PIK3CB, POLB, PTGS1, PTGS2 |
| BP | GO:0009987; cellular process | GO:0043066; negative regulation of apoptotic process | 4.554E-09 | 7.628E-06 | ADORA1, ADORA2A, ALOX12, AURKB, AXL, CDK1, IGF1R, KDR, LMNA, NFKB1, PIK3CA, PIM1, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 8.084E-09 | 1.174E-05 | CA1, CA12, CA2, CA7, CA9 |
| MF | GO:0060089; molecular transducer activity | GO:0001609; G-protein coupled adenosine receptor activity | 2.445E-07 | 1.704E-04 | ADORA1, ADORA2A, ADORA3 |
| BP | GO:0009987; cellular process | GO:0001973; adenosine receptor signaling pathway | 5.852E-07 | 3.186E-04 | ADORA1, ADORA2A, ADORA3 |
| MF | GO:0005488; binding | GO:0043560; insulin receptor substrate binding | 1.146E-06 | 5.674E-04 | IGF1R, PIK3CA, PIK3CB |
| BP | GO:0023052; signaling | GO:0032230; positive regulation of synaptic transmission, GABAergic | 1.982E-06 | 8.807E-04 | ADORA2A, CA2, CA7 |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 3.004E-06 | 1.271E-03 | ADORA1, ADORA2A, CA2, CA7, KDR, NPSR1 |
| MF | GO:0003824; catalytic activity | GO:0004666; prostaglandin-endoperoxide synthase activity | 3.769E-06 | 1.351E-03 | PTGS1, PTGS2 |
| MF | GO:0005488; binding | GO:0046914; transition metal ion binding | 4.356E-06 | 1.530E-03 | ALOX12, CA1, CA12, CA2, CA7, CA9, CYP1B1, CYP3A4, ESR1, NQO2, PIM1 |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 4.789E-06 | 1.604E-03 | ALPL, CYP1B1, ESR1, FLT3, NFKB1, NOX4, PTGS2 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 4.976E-06 | 1.642E-03 | CYP1B1, CYP3A4, NOX4, PTGS1, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 6.462E-06 | 2.039E-03 | AKR1B10, ALOX12, CYP1B1, CYP3A4, GFER, HSD17B10, NOX4, NQO2, PTGS1, PTGS2 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.129E-05 | 2.998E-03 | CA2, CA7 |
| CC | GO:0044464; cell part | GO:0099056; integral component of presynaptic membrane | 1.129E-05 | 2.998E-03 | ADORA1, ADORA2A |
| BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 1.150E-05 | 3.017E-03 | AXL, MET, NOX4, PIK3CA, PIK3CB |
| BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 1.190E-05 | 3.058E-03 | AXL, KDR, PIK3CA, PIK3CB |
| BP | GO:0008152; metabolic process | GO:0018108; peptidyl-tyrosine phosphorylation | 3.043E-05 | 6.310E-03 | AXL, FLT3, IGF1R, KDR, MET |
| BP | GO:0008152; metabolic process | GO:0046777; protein autophosphorylation | 3.908E-05 | 7.737E-03 | AURKB, FLT3, IGF1R, KDR, PIM1 |
| BP | GO:0050896; response to stimulus | GO:0006979; response to oxidative stress | 5.128E-05 | 9.544E-03 | AXL, CDK1, CYP1B1, NOX4, PTGS1, PTGS2 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 3.789E-13 | 5.494E-11 | CA12, CA1, CA2, CA7, CA9, CA14 |
| 09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 7.341E-08 | 3.548E-06 | PIK3CA, FLT3, PIM1, PIK3CB, NFKB1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04923 | Regulation of lipolysis in adipocytes | 6.706E-08 | 3.548E-06 | PIK3CA, ADORA1, PIK3CB, PTGS2, PTGS1 |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 2.139E-06 | 7.404E-05 | PIK3CA, KDR, PIK3CB, ESR1, MET, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 2.675E-06 | 7.404E-05 | PIK3CA, ADORA2A, KDR, PIK3CB, MET, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 4.078E-06 | 8.447E-05 | PIK3CA, KDR, PIK3CB, MET, NFKB1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 8.547E-06 | 1.239E-04 | PIK3CA, FLT3, PIK3CB, PTGS2, MET, NFKB1, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04370 | VEGF signaling pathway | 5.349E-06 | 9.694E-05 | PIK3CA, KDR, PIK3CB, PTGS2 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04071 | Sphingolipid signaling pathway | 3.064E-06 | 7.404E-05 | PIK3CA, ADORA3, ADORA1, PIK3CB, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 7.792E-06 | 1.239E-04 | PIK3CA, FLT3, PIK3CB, MET |
| 09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 9.824E-06 | 1.255E-04 | PIK3CA, PIK3CB, MET, IGF1R |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 1.039E-05 | 1.255E-04 | PIK3CA, PIK3CB, ESR1, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 1.887E-05 | 2.105E-04 | PIK3CA, PIM1, CYP1B1, PTGS2, MET, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 2.409E-05 | 2.329E-04 | PIK3CA, PIK3CB, NFKB1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05222 | Small cell lung cancer | 2.104E-05 | 2.179E-04 | PIK3CA, PIK3CB, PTGS2, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 4.095E-05 | 2.698E-04 | PIK3CA, KDR, PIK3CB, MET, NFKB1, IGF1R |
| 09150 Organismal Systems | 09149 Aging | hsa04211 | Longevity regulating pathway - mammal | 2.988E-05 | 2.698E-04 | PIK3CA, PIK3CB, NFKB1, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 3.565E-05 | 2.698E-04 | PIK3CA, ADORA2A, ADORA1, PIK3CB, NFKB1 |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 3.963E-05 | 2.698E-04 | PIK3CA, PIM1, PIK3CB, NFKB1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04914 | Progesterone-mediated oocyte maturation | 3.521E-05 | 2.698E-04 | PIK3CA, CDK1, PIK3CB, IGF1R |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 3.829E-05 | 2.698E-04 | PIK3CA, KDR, PIK3CB, MET, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 4.107E-05 | 2.698E-04 | POLB, PIK3CA, CDK1, PIK3CB, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04668 | TNF signaling pathway | 5.536E-05 | 3.344E-04 | PIK3CA, PIK3CB, PTGS2, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 4.280E-05 | 2.698E-04 | PIK3CA, PIK3CB, NFKB1, IGF1R |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 1.411E-04 | 7.870E-04 | PIK3CA, LMNA, PIK3CB, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04022 | cGMP-PKG signaling pathway | 2.774E-04 | 1.257E-03 | PIK3CA, ADORA3, ADORA1, PIK3CB |
| 09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 2.548E-04 | 1.247E-03 | PIK3CA, PIK3CB, IGF1R |
| 09150 Organismal Systems | 09149 Aging | hsa04213 | Longevity regulating pathway - multiple species | 2.434E-04 | 1.247E-03 | PIK3CA, PIK3CB, IGF1R |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 1.166E-04 | 6.763E-04 | CYP1B1, PTGS2, IGF1R |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 2.215E-04 | 1.190E-03 | ALOX12, PTGS2, PTGS1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05169 | Epstein-Barr virus infection | 5.698E-04 | 2.119E-03 | PIK3CA, CDK1, PIK3CB, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 2.666E-04 | 1.247E-03 | PIK3CA, PIK3CB, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 3.688E-04 | 1.485E-03 | FLT3, MET, NFKB1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05211 | Renal cell carcinoma | 2.666E-04 | 1.247E-03 | PIK3CA, PIK3CB, MET |
| 09160 Human Diseases | 09161 Cancers | hsa05220 | Chronic myeloid leukemia | 3.591E-04 | 1.485E-03 | PIK3CA, PIK3CB, NFKB1 |
| 09150 Organismal Systems | 09151 Immune system | hsa04662 | B cell receptor signaling pathway | 3.591E-04 | 1.485E-03 | PIK3CA, PIK3CB, NFKB1 |
| 09150 Organismal Systems | 09157 Sensory system | hsa04750 | Inflammatory mediator regulation of TRP channels | 8.498E-04 | 3.080E-03 | PIK3CA, ALOX12, PIK3CB |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 8.752E-04 | 3.095E-03 | PIK3CA, PIK3CB, ESR1 |
| 09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 3.308E-04 | 1.454E-03 | CA2, SLCO1B3, CYP3A4 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05100 | Bacterial invasion of epithelial cells | 4.363E-04 | 1.710E-03 | PIK3CA, PIK3CB, MET |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05146 | Amoebiasis | 9.011E-04 | 3.111E-03 | PIK3CA, PIK3CB, NFKB1 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04725 | Cholinergic synapse | 1.218E-03 | 3.759E-03 | ACHE, PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09151 Immune system | hsa04660 | T cell receptor signaling pathway | 1.009E-03 | 3.327E-03 | PIK3CA, PIK3CB, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05166 | HTLV-I infection | 1.415E-03 | 4.131E-03 | POLB, PIK3CA, PIK3CB, NFKB1 |
| 09150 Organismal Systems | 09151 Immune system | hsa04620 | Toll-like receptor signaling pathway | 1.067E-03 | 3.437E-03 | PIK3CA, PIK3CB, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05142 | Chagas disease (American trypanosomiasis) | 1.009E-03 | 3.327E-03 | PIK3CA, PIK3CB, NFKB1 |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04931 | Insulin resistance | 1.156E-03 | 3.645E-03 | PIK3CA, PIK3CB, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 5.053E-04 | 1.928E-03 | CYP1B1, CYP3A4, PTGS2 |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 1.955E-03 | 5.115E-03 | AKR1B10, ADK, ALPL, ALOX12, PTGS2, CYP3A4, HSD17B10, PTGS1 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 1.250E-03 | 3.777E-03 | ALOX12, PTGS2, PTGS1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05145 | Toxoplasmosis | 1.453E-03 | 4.131E-03 | PIK3CA, PIK3CB, NFKB1 |
| 09150 Organismal Systems | 09151 Immune system | hsa04611 | Platelet activation | 1.599E-03 | 4.374E-03 | PIK3CA, PIK3CB, PTGS1 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04722 | Neurotrophin signaling pathway | 1.525E-03 | 4.251E-03 | PIK3CA, PIK3CB, NFKB1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 1.453E-03 | 4.131E-03 | PIK3CA, PIK3CB, ESR1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04152 | AMPK signaling pathway | 1.675E-03 | 4.497E-03 | PIK3CA, PIK3CB, IGF1R |
| 09150 Organismal Systems | 09158 Development | hsa04380 | Osteoclast differentiation | 2.002E-03 | 5.115E-03 | PIK3CA, PIK3CB, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05160 | Hepatitis C | 2.046E-03 | 5.115E-03 | PIK3CA, PIK3CB, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05162 | Measles | 2.180E-03 | 5.358E-03 | PIK3CA, PIK3CB, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04068 | FoxO signaling pathway | 2.046E-03 | 5.115E-03 | PIK3CA, PIK3CB, IGF1R |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 2.666E-03 | 6.236E-03 | PIK3CA, PIK3CB, NFKB1 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 2.464E-03 | 5.923E-03 | PIK3CA, PIK3CB, IGF1R |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04932 | Non-alcoholic fatty liver disease (NAFLD) | 2.933E-03 | 6.750E-03 | PIK3CA, PIK3CB, NFKB1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04921 | Oxytocin signaling pathway | 3.332E-03 | 7.320E-03 | PIK3CA, PIK3CB, PTGS2 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04630 | Jak-STAT signaling pathway | 3.332E-03 | 7.320E-03 | PIK3CA, PIM1, PIK3CB |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05164 | Influenza A | 4.437E-03 | 9.323E-03 | PIK3CA, PIK3CB, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05213 | Endometrial cancer | 4.390E-03 | 9.323E-03 | PIK3CA, PIK3CB |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04930 | Type II diabetes mellitus | 3.753E-03 | 8.121E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09154 Digestive system | hsa04973 | Carbohydrate digestion and absorption | 3.305E-03 | 7.320E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09155 Excretory system | hsa04960 | Aldosterone-regulated sodium reabsorption | 2.492E-03 | 5.923E-03 | PIK3CA, PIK3CB |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | PTGS1; |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1; |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | ADORA1; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; |
| C00-D49: Neoplasms | Prostate cancer | C61 | ESR1; FLT3; |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; PTGS2; |
| C00-D49: Neoplasms | Renal cancer | C64 | KDR; CA9; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
| N00-N99: Diseases of the genitourinary system | Renal failure | N17, N18, N19 | ADORA1; |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; |
| NA: NA | Menopausal disorder | NA | ESR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | ADK; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Convulsions | R56.0 | ADK; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | PTGS1; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Radionuclide imaging | W88 | ADORA2A; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; PTGS2; |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3; |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | PTGS2; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ADORA2A; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; CA2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2; |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; CA1; |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS1; PTGS2; |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1; |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1; PTGS1; |
| I00-I99: Diseases of the circulatory system | Acute and chronic heart failure | I50 | ADORA1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; ACHE; |
| A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL; |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1; |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
| C00-D49: Neoplasms | CLL | NA | FLT3; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; PTGS2; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ADORA1; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; PTGS2; |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADORA2A; |
| C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | ADORA1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | PTGS1; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | PIK3CB; |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1; |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
| C00-D49: Neoplasms | Breast cancer | C50 | ESR1; CDK1; IGF1R; KDR; FLT3; NQO2; CA9; |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1; |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | ADORA1; |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1; ADORA1; |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2; |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1; |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1; |
| C00-D49: Neoplasms | Cancer | C00-C96 | ESR1; PIM1; MET; CDK1; IGF1R; PIK3CA; KDR; NFKB1; FLT3; ACHE; ADORA3; PTGS2; PIK3CB; NQO2; CA1; CA9; |
| NA: NA | Postmenopausal disorder | NA | ESR1; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| NA: NA | Edema | NA | CA2; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PTGS2; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; ADORA1; |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | ADORA1; ADORA2A; PTGS1; PTGS2; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1; PTGS1; PTGS2; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2; |
| NA: NA | Miosis during ocular surgery | NA | PTGS1; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | ADORA2A; |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; ADK; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1; ADORA1; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADORA1; ADORA2A; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypertriglyceridemia | E78.1, E78.2, E78.3, I47-I49 | ADORA1; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ADORA1; ADORA2A; PTGS2; |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | ADORA2A; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1; |
| I00-I99: Diseases of the circulatory system | Coronary disorder diagnosis | I20-I25 | ADORA2A; |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; PTGS1; |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; ALPL; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; NPSR1; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; ADORA3; |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
| NA: NA | Hepatitis C virus infection | NA | ADORA3; |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | ADORA1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1; |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1; |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; IGF1R; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS1; PTGS2; |
| A00-B99: Certain infectious and parasitic diseases | Sepsis | A40, A41 | ADORA1; |
| I00-I99: Diseases of the circulatory system | Orthostatic hypotension | I95.1 | ADORA1; |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1; |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; ADORA1; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; ADORA1; ADORA2A; ADORA3; CA1; |
| C00-D49: Neoplasms | Glioma | C71 | KDR; |
| NA: NA | Rheumatold arthritis | NA | PTGS1; PTGS2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2; |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PIK3CA; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | ESR1; FLT3; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADORA1; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; AURKB; IGF1R; PIK3CA; KDR; FLT3; PIK3CB; CA9; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1; |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1; |
| NA: NA | Joint and muscular pain | NA | PTGS2; |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3; |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PTGS2; |
| I00-I99: Diseases of the circulatory system | Cardiac disease | I00-I99 | ADORA1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PTGS1; PTGS2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ADORA3; PTGS2; |
| NA: NA | GIST | NA | FLT3; |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PTGS2; |
| NA: NA | Gonorrheal vaginitis | NA | ESR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; ADORA1; ADORA2A; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1; CDK1; IGF1R; ACHE; ADORA2A; ADK; PTGS1; PTGS2; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1; |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
